Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:39 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 7,441 matching trials from the live ClinicalTrials.gov search.

Filters: Aurora, Colorado Clear all

Conditions: Klinefelter Syndrome, XXY Syndrome
Interventions: Testosterone gel 1%, Placebo gel; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HIV Infections, Influenza
Interventions: Cold-adapted live attenuated influenza vaccine (FluMist), Inactivated influenza vaccine (IAIV); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 42 more

Conditions: Multiple Sclerosis, Acute Relapsing
Interventions: rHIgM22, Placebo; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 12
States / cities: Long Beach, California • Sacramento, California • San Francisco, California + 8 more

Conditions: Glioblastoma
Interventions: Azeliragon; Drug
Lead sponsor: Cantex Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Aurora, Colorado • Miami, Florida • Royal Oak, Michigan + 5 more

Conditions: Asthma in Children, Asthma Chronic
Interventions: Asthma Ctrl+, Control; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Aurora, Colorado • Cincinnati, Ohio

Conditions: Thyroid Eye Disease
Interventions: Veligrotug, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 29
States / cities: Aurora, California • Beverly Hills, California • Los Angeles, California + 22 more

Conditions: Type 2 Diabetes Mellitus
Interventions: High-dose colesevelam, Low-dose colesevelam; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 24
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Curcumin, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 6 Years to 25 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: NASH, Cirrhosis, Liver
Interventions: Resmetirom, Placebo; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 845 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 96
States / cities: Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more

Conditions: Opioid-Induced Constipation
Interventions: Methylnaltrexone, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 29
States / cities: Mobile, Alabama • Laguna Hills, California • Lancaster, California + 23 more

Conditions: Melanoma
Interventions: YM155; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 9
States / cities: Tuscon, Arizona • Little Rock, Arkansas • Aurora, Colorado + 6 more

Conditions: Thrombosis
Interventions: Apixaban, Vitamin K Antagonist (VKA), Low Molecular Weight Heparin (LMWH); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 28 Days to 17 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 14
States / cities: Phoenix, Arizona • La Jolla, California • Aurora, Colorado + 11 more

Conditions: Pancreatic Cancer
Interventions: ABBV-927, Budiglimab, modified FOLFIRINOX; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: Aurora, Colorado • Baltimore, Maryland • Cleveland, Ohio + 1 more

Conditions: Asthma, Obesity
Interventions: CXA-10, Matching Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions: Tacrolimus, Sirolimus; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 25
States / cities: La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more

Conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
Interventions: Nab paclitaxel, Gemcitabine; Drug
Lead sponsor: Academic Thoracic Oncology Medical Investigators Consortium; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 4
States / cities: Scottsdale, Arizona • Tucson, Arizona • Aurora, Colorado + 1 more

Conditions: Melanoma
Interventions: CP-675,206; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 8
States / cities: Scottsdale, Arizona • Aurora, Colorado • Aventura, Florida + 5 more

Conditions: Dravet Syndrome
Interventions: LP352, Placebo; Drug
Lead sponsor: Longboard Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 20 more

Conditions: Type 1 Diabetes
Interventions: Metformin, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypoplastic Left Heart Syndrome (HLHS)
Interventions: Collaborative Learning Network; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Up to 15 Months
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 53 more

Conditions: Obesity, Diabetes
Interventions: Time Restricted Feeding; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: HPV Immunization Status
Interventions: Multimodal Vaccine Program; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 9 Years and older
Enrollment: 93,582 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Willpower
Interventions: Sequence 1, Sequence 2, Sequence 3, Sequence 4; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype, Lung Small Cell Carcinoma, I Subtype, Lung Small Cell Carcinoma, N Subtype, Lung Small Cell Carcinoma, P Subtype
Interventions: Biospecimen Collection, Ceralasertib, Computed Tomography, Durvalumab, Etoposide, Magnetic Resonance Imaging, Monalizumab, Platinum Compound, Positron Emission Tomography, Saruparib, Thoracic Radiation Therapy; Procedure · Drug · Biological + 1 more
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 148
States / cities: Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more

Search by objective public record fields.

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

Azeliragon in MGMT Unmethylated Glioblastoma

Asthma Ctrl SMART Trial

A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)

Colesevelam for Children With Type 2 Diabetes

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

Time Restricted Feeding and Metabolic Rhythms

Strengthening Physician Communication About HPV Vaccines

A Pilot Study: Snacking, Willpower and Glucose Availability

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study